HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 167 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q1 2017 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q4 2016 | $1,000 | -66.7% | 100 | -66.7% | 0.00% | -100.0% |
| Q2 2016 | $3,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $3,000 | -82.4% | 300 | -70.0% | 0.00% | -80.0% |
| Q4 2015 | $17,000 | +30.8% | 1,000 | 0.0% | 0.01% | +25.0% |
| Q3 2015 | $13,000 | -80.9% | 1,000 | -66.7% | 0.00% | -78.9% |
| Q2 2015 | $68,000 | +58.1% | 3,000 | 0.0% | 0.02% | +58.3% |
| Q1 2015 | $43,000 | +48.3% | 3,000 | 0.0% | 0.01% | +100.0% |
| Q4 2014 | $29,000 | +7.4% | 3,000 | 0.0% | 0.01% | +20.0% |
| Q3 2014 | $27,000 | -22.9% | 3,000 | -14.3% | 0.01% | -28.6% |
| Q2 2014 | $35,000 | -47.8% | 3,500 | -33.3% | 0.01% | -46.2% |
| Q1 2014 | $67,000 | -15.2% | 5,250 | 0.0% | 0.01% | +18.2% |
| Q4 2013 | $79,000 | +259.1% | 5,250 | +162.5% | 0.01% | +266.7% |
| Q3 2013 | $22,000 | +37.5% | 2,000 | 0.0% | 0.00% | 0.0% |
| Q2 2013 | $16,000 | – | 2,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,816,162 | $191,226,000 | 8.73% |
| BB BIOTECH AG | 6,825,532 | $65,866,000 | 2.13% |
| Lombard Odier Asset Management (USA) Corp | 2,700,000 | $26,055,000 | 1.79% |
| SECTORAL ASSET MANAGEMENT INC | 3,724,351 | $35,940,000 | 1.61% |
| QVT Financial LP | 2,010,186 | $19,398,000 | 0.97% |
| JHL Capital Group LLC | 1,475,000 | $14,234,000 | 0.94% |
| MAZAMA CAPITAL MANAGEMENT INC | 358,087 | $3,456,000 | 0.79% |
| EcoR1 Capital, LLC | 160,700 | $1,551,000 | 0.78% |
| Alden Global Capital Ltd | 332,500 | $3,209,000 | 0.77% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 7,274,065 | $70,195,000 | 0.65% |